Rilpivirine hydrochlorideProduct ingredient for Rilpivirine

Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients.¹ It is a diarylpyrimidine derivative.² The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's.³ Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011.⁶ On November 21, 2017, Rilpivirine, in combination with dolutegravir, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca.⁷ Rilpivirine in combination with cabotegravir was granted FDA approval on 21 January 2021.¹⁰ While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 ¹¹ and without the need for an oral lead-in period prior.¹⁰